AI assistant
Sending…
VYNE Therapeutics Inc. — Director's Dealing 2021
Aug 26, 2021
35290_dirs_2021-08-26_2dfa440c-7907-4462-84f4-2caae9d4a5fa.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VYNE Therapeutics Inc. (VYNE)
CIK: 0001566044
Period of Report: 2021-08-25
Reporting Person: LEPORE PATRICK G (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-08-25 | Common Stock | P | 12500 | $1.60 | Acquired | 50000 | Direct |
Footnotes
F1: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.59 to $1.60, inclusive. The reporting person undertakes to provide to VYNE Therapeutics Inc., any security holder of VYNE Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
More from VYNE Therapeutics Inc.
Regulatory Filings
2026
May 21
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
Apr 28
Regulatory Filings
2026
Mar 31
Annual Report
2026
Feb 27
Regulatory Filings
2026
Jan 30
Regulatory Filings
2026
Jan 30
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5